GlassScriptPhysician profile
Anisha Antony
NPI 1033995154
$3,691.99
in general payments reported to CMS, 2019-2025
33 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.98 · 2024: $1,591 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $552.61 | 2024-2025 | Evenity, Repatha, Repatha |
| Gilead Sciences, INC. | $408.37 | 2024-2025 | Livdelzi |
| Astrazeneca Pharmaceuticals LP | $374.92 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $349.76 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $266.88 | 2024-2025 | |
| Abbvie INC. | $252.50 | 2024-2025 | |
| Novo Nordisk INC | $230.10 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $173.85 | 2024-2025 | Rexulti |
| Lundbeck LLC | $107.09 | 2023-2025 | Rexulti |
| Verity Pharmaceuticals INC. | $95.11 | 2024-2025 | Tlando |
| Merck Sharp & Dohme LLC | $94.54 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.43 | 2024-2025 | Jardiance, Jascayd |
| Optinose US, INC. | $68.56 | 2025 | |
| Novartis Pharmaceuticals Corporation | $68.25 | 2025 | |
| Pfizer INC. | $67.29 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.84 | 2025 | Veozah |
| Corcept Therapeutics | $59.20 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $56.26 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $50.46 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $39.79 | 2024-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $24.59 | 2025 | Voquezna |
| Tolmar, INC. | $23.39 | 2025 | Jatenzo |
| Antares Pharma, INC. | $22.12 | 2024 | Xyosted |
| Collegium Pharmaceutical, INC. | $22.03 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $20.99 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $18.56 | 2024 | Livalo |
| Impulse Dynamics (USA) INC. | $18.14 | 2024 | Optimizer |
| Biomerieux INC | $18.00 | 2025 | Biofire Spotfire Control Station |
| Redhill Biopharma INC. | $17.16 | 2024 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.68 | 2023 | Xifaxan |
| Philips North America LLC | $14.57 | 2025 | Vest Therapy Und |
| Evoke Pharma, INC. | $14.01 | 2025 | |
| Currax Pharmaceuticals LLC | $12.94 | 2023 | Nexletol, Contrave, Nexlizet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisha Antony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.